Emergent BioSolutions (EBS) Payables (2010 - 2026)

Emergent BioSolutions' Payables history runs 17 years deep, the most recent figure standing at $39.5 million for Q1 2026.

• In Q1 2026, Payables fell 32.01% year-over-year to $39.5 million; the TTM figure through Mar 2026 stood at $39.5 million (down 32.01% YoY), while the FY2025 annual figure was $55.6 million, down 8.7% from the prior year.
• Payables was $39.5 million for Q1 2026 at Emergent BioSolutions, down from $55.6 million in the prior quarter.
• In the past five years, Payables ranged from a high of $1.1 billion in Q1 2023 to a low of $39.5 million in Q1 2026.
• Historically, Payables has averaged $331.7 million across 5 years, with a median of $137.8 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Payables jumped 673.87% in 2023, then plunged 89.61% in 2025.
• A 5-year view of Payables shows it stood at $1.1 billion in 2022, then plunged by 50.42% to $525.9 million in 2023, then sank by 88.42% to $60.9 million in 2024, then slipped by 8.7% to $55.6 million in 2025, then fell by 28.96% to $39.5 million in 2026.
• The last three Payables figures came in at $39.5 million (Q1 2026), $55.6 million (Q4 2025), and $57.4 million (Q3 2025), per Business Quant data.